Nyxol meets primary endpoint in trial evaluating reversal of mydriasis

In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, according to a press release from Ocuphire Pharma.
The drop, an investigational formulation of phentolamine mesylate, is designed to reduce pupil size by inhibiting contraction of the iris dilator muscle. Efficacy and safety of the drop were evaluated in the MIRA-3 trial in 368 participants who underwent pharmacologically induced mydriasis.
Among those who received Nyxol, 58% met the primary endpoint and returned to 0.2 mm or less of baseline pupil diameter at 90 minutes compared with

In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, according to a press release from Ocuphire Pharma.
The drop, an investigational formulation of phentolamine mesylate, is designed to reduce pupil size by inhibiting contraction of the iris dilator muscle. Efficacy and safety of the drop were evaluated in the MIRA-3 trial in 368 participants who underwent pharmacologically induced mydriasis.
Among those who received Nyxol, 58% met the primary endpoint and returned to 0.2 mm or less of baseline pupil diameter at 90 minutes compared with